• Tim Lahm, Ivor S Douglas, Stephen L Archer, Harm J Bogaard, Naomi C Chesler, Francois Haddad, Anna R Hemnes, Steven M Kawut, Jeffrey A Kline, Todd M Kolb, Stephen C Mathai, Olaf Mercier, Evangelos D Michelakis, Robert Naeije, Rubin M Tuder, Corey E Ventetuolo, Antoine Vieillard-Baron, Norbert F Voelkel, Anton Vonk-Noordegraaf, Paul M Hassoun, and American Thoracic Society Assembly on Pulmonary Circulation.
• Am. J. Respir. Crit. Care Med. 2018 Aug 15; 198 (4): e15-e43.

BackgroundRight ventricular (RV) adaptation to acute and chronic pulmonary hypertensive syndromes is a significant determinant of short- and long-term outcomes. Although remarkable progress has been made in the understanding of RV function and failure since the meeting of the NIH Working Group on Cellular and Molecular Mechanisms of Right Heart Failure in 2005, significant gaps remain at many levels in the understanding of cellular and molecular mechanisms of RV responses to pressure and volume overload, in the validation of diagnostic modalities, and in the development of evidence-based therapies.MethodsA multidisciplinary working group of 20 international experts from the American Thoracic Society Assemblies on Pulmonary Circulation and Critical Care, as well as external content experts, reviewed the literature, identified important knowledge gaps, and provided recommendations.ResultsThis document reviews the knowledge in the field of RV failure, identifies and prioritizes the most pertinent research gaps, and provides a prioritized pathway for addressing these preclinical and clinical questions. The group identified knowledge gaps and research opportunities in three major topic areas: 1) optimizing the methodology to assess RV function in acute and chronic conditions in preclinical models, human studies, and clinical trials; 2) analyzing advanced RV hemodynamic parameters at rest and in response to exercise; and 3) deciphering the underlying molecular and pathogenic mechanisms of RV function and failure in diverse pulmonary hypertension syndromes.ConclusionsThis statement provides a roadmap to further advance the state of knowledge, with the ultimate goal of developing RV-targeted therapies for patients with RV failure of any etiology.

18 keywords...

hide…